Study of Alemtuzumab Versus Anti-Thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation - Related Studies

Study of Alemtuzumab Versus Anti-Thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

This study is currently recruiting participants.

Study NCT00331162. Last updated on July 23, 2008. Information provided by Wake Forest University Baptist Medical Center

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Graft Rejection

2	Interventions listed in this trial
		Alemtuzumab
		Anti-Thymocyte Globulin

3	Additional drug interventions recognized in this trial
		Antilymphocyte Serum
		Pancrelipase

4	More general drug interventions related to this trial
		Antineoplastic Agents
		Gastrointestinal Agents
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

5	Sponsors listed in this trial
		Wake Forest University Baptist Medical Center